WO2001098512A3 - Control of metabolism with compositions of the human 2-oxoglutarate carrier - Google Patents

Control of metabolism with compositions of the human 2-oxoglutarate carrier Download PDF

Info

Publication number
WO2001098512A3
WO2001098512A3 PCT/US2001/020020 US0120020W WO0198512A3 WO 2001098512 A3 WO2001098512 A3 WO 2001098512A3 US 0120020 W US0120020 W US 0120020W WO 0198512 A3 WO0198512 A3 WO 0198512A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
human
metabolism
control
oxoglutarate carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/020020
Other languages
French (fr)
Other versions
WO2001098512A2 (en
Inventor
Sean Adams
Xing Xian Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU7139501A priority Critical patent/AU7139501A/en
Priority to EP01950401A priority patent/EP1294881B1/en
Priority to DE60105609T priority patent/DE60105609T8/en
Priority to AU2001271395A priority patent/AU2001271395B2/en
Priority to CA002414033A priority patent/CA2414033A1/en
Priority to AT01950401T priority patent/ATE276363T1/en
Publication of WO2001098512A2 publication Critical patent/WO2001098512A2/en
Anticipated expiration legal-status Critical
Publication of WO2001098512A3 publication Critical patent/WO2001098512A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

The present invention is directed to compositions and methods related to the use of human OGC as an uncoupling protein.
PCT/US2001/020020 2000-06-22 2001-06-22 Control of metabolism with compositions of the human 2-oxoglutarate carrier Ceased WO2001098512A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU7139501A AU7139501A (en) 2000-06-22 2001-06-22 Control of metabolism with compositions of the human 2-oxoglutarate carrier
EP01950401A EP1294881B1 (en) 2000-06-22 2001-06-22 Control of metabolism with compositions of the human 2-oxoglutarate carrier
DE60105609T DE60105609T8 (en) 2000-06-22 2001-06-22 METABOLISM CONTROL BY COMPOSITIONS OF THE HUMAN 2-OXOGLUTAR CARRIER
AU2001271395A AU2001271395B2 (en) 2000-06-22 2001-06-22 Control of metabolism with compositions of the human 2-oxoglutarate carrier
CA002414033A CA2414033A1 (en) 2000-06-22 2001-06-22 Control of metabolism with compositions of the human 2-oxoglutarate carrier
AT01950401T ATE276363T1 (en) 2000-06-22 2001-06-22 METABOLISM CONTROL USING HUMAN 2-OXOGLUTARATE CARRIER COMPOSITIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21330700P 2000-06-22 2000-06-22
US60/213,307 2000-06-22

Publications (2)

Publication Number Publication Date
WO2001098512A2 WO2001098512A2 (en) 2001-12-27
WO2001098512A3 true WO2001098512A3 (en) 2003-01-03

Family

ID=22794566

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/020117 Ceased WO2001098355A2 (en) 2000-06-22 2001-06-22 Cgi-69 compositions and methods of use
PCT/US2001/020020 Ceased WO2001098512A2 (en) 2000-06-22 2001-06-22 Control of metabolism with compositions of the human 2-oxoglutarate carrier

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020117 Ceased WO2001098355A2 (en) 2000-06-22 2001-06-22 Cgi-69 compositions and methods of use

Country Status (7)

Country Link
US (2) US20020119137A1 (en)
EP (2) EP1294877B1 (en)
AT (2) ATE276363T1 (en)
AU (4) AU2001271395B2 (en)
CA (2) CA2414033A1 (en)
DE (2) DE60105609T8 (en)
WO (2) WO2001098355A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE276363T1 (en) 2000-06-22 2004-10-15 Genentech Inc METABOLISM CONTROL USING HUMAN 2-OXOGLUTARATE CARRIER COMPOSITIONS
US20100209960A1 (en) * 2007-09-10 2010-08-19 Merck Sharp & Dohme Corp. Method for measuring mitochondrial membrane potential in vertebrate cells
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
CN109629463B (en) * 2019-01-23 2023-12-08 河南中平交科研究设计院有限公司 Bridge end reinforcing structure and bridge plate end crack treatment process
CN114837060B (en) * 2022-03-29 2024-01-12 江苏远方交通勘察设计研究院有限公司 A safe temporary plank road structure for bridge construction projects

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
WO1999064458A1 (en) * 1998-06-08 1999-12-16 Trustees Of Boston University Novel methods for identifying modulators of mitochondrial anion carrier activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
WO2000004037A1 (en) 1998-07-14 2000-01-27 Amylin Pharmaceuticals, Inc. Uncoupling protein 4 (ucp-4) and methods of use
AU4081000A (en) 1999-04-09 2000-11-14 Human Genome Sciences, Inc. Uncoupling proteins
ATE276363T1 (en) 2000-06-22 2004-10-15 Genentech Inc METABOLISM CONTROL USING HUMAN 2-OXOGLUTARATE CARRIER COMPOSITIONS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
WO1999064458A1 (en) * 1998-06-08 1999-12-16 Trustees Of Boston University Novel methods for identifying modulators of mitochondrial anion carrier activity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAS KALLOL ET AL: "Predominant expression of the mitochondrial dicarboxylate carrier in white adipose tissue.", BIOCHEMICAL JOURNAL, vol. 344, no. 2, 1 December 1999 (1999-12-01), pages 313 - 320, XP008003598, ISSN: 0264-6021 *
DATABASE EMBL [online] EBI, Hinxton, UK; 5 December 1999 (1999-12-05), YU AND GIBBS: "Homo sapiens clone 24408 2-oxoglutarate carrier protein mRNA, complete cds.", XP002200191, Database accession no. AF070548 *
JEZEK P ET AL: "Fatty acid cycling mechanism and mitochondrial uncoupling proteins", BIOCHIMICA ET BIOPHYSICA ACTA. BIOENERGETICS, AMSTERDAM, NL, vol. 1365, no. 1-2, 10 June 1998 (1998-06-10), pages 319 - 327, XP004338771, ISSN: 0005-2728 *
WALKER JOHN E ET AL: "The mitochondrial transport protein superfamily.", JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, vol. 25, no. 5, 1993, pages 435 - 446, XP002089542, ISSN: 0145-479X *
YU XING XIAN ET AL: "Overexpression of the human 2-oxoglutarate carrier lowers mitochondrial membrane potential in HEK-293 cells: Contrast with the unique cold-induced mitochondrial carrier CGI-69.", BIOCHEMICAL JOURNAL, vol. 353, no. 2, 15 January 2001 (2001-01-15), pages 369 - 375, XP001059156, ISSN: 0264-6021 *
ZHANG CHEN-YU ET AL: "Assessment of uncoupling activity of uncoupling protein 3 using a yeast heterologous expression system.", FEBS LETTERS, vol. 449, no. 2-3, 23 April 1999 (1999-04-23), pages 129 - 134, XP002200190, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
US20020119137A1 (en) 2002-08-29
EP1294881A2 (en) 2003-03-26
CA2414065A1 (en) 2001-12-27
EP1294881B1 (en) 2004-09-15
AU7139501A (en) 2002-01-02
US7141421B2 (en) 2006-11-28
WO2001098355A2 (en) 2001-12-27
DE60113535T2 (en) 2006-06-22
AU6871501A (en) 2002-01-02
ATE276363T1 (en) 2004-10-15
CA2414033A1 (en) 2001-12-27
WO2001098512A2 (en) 2001-12-27
DE60113535D1 (en) 2006-02-02
WO2001098355A3 (en) 2002-10-03
US20020103150A1 (en) 2002-08-01
EP1294877A2 (en) 2003-03-26
DE60105609T2 (en) 2005-09-22
AU2001268715B2 (en) 2007-01-11
ATE305041T1 (en) 2005-10-15
DE60105609T8 (en) 2006-02-16
AU2001271395B2 (en) 2007-02-08
EP1294877B1 (en) 2005-09-21
DE60105609D1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2002016429A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003000113A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
WO2004001019A3 (en) Novel nanoparticles and use thereof
AU2001282399A1 (en) Resorcinol derivatives
AU2001241474A1 (en) Biosensor compositions and methods of use
WO2002016581A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002024613A3 (en) Resorcinol derivatives
WO2004024063A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002343601A1 (en) Proteins involved in regulation of adipocytes and uses related thereto
WO2002098386A3 (en) Use of sodium polystyrene sulfonate for tightening skin
AU7139501A (en) Control of metabolism with compositions of the human 2-oxoglutarate carrier
AU2001289864A1 (en) Regulation of human protein disulfide isomerase-like enzyme
MXPA03004539A (en) Isolated luciferases and the use thereof.
WO2003002077A3 (en) Reduction of hair growth
AU2001240025A1 (en) Cell cycle proteins associated with rad9, compositions and methods of use
EP1475439A3 (en) Control of metabolism with compositions of the human 2-oxoglutarate carrier
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2002246585A1 (en) Plant promoters, and methods of use
AU2001297575A1 (en) 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
WO2001083550A3 (en) Gpr22 modulators as appetite-control agents
AU2001267699A1 (en) Testing of leather
AU2001273245A1 (en) Modulators of trk protein activity, compositions and uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001271395

Country of ref document: AU

Ref document number: 2414033

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001950401

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001950401

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001950401

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001271395

Country of ref document: AU